Acrivon (NASDAQ: ACRV) is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates, referred to as patient responders. The name Acrivon (derived from Greek for “accurate”) embodies how our OncoSignature tests link the patient’s active tumor-driving mechanisms with the drug’s mode-of-action to accurately match our therapies with patients who will benefit independent of underlying genetic tumor alterations.

Acrivon is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. The company has received fast track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer. Acrivon’s ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third party Phase 2 trials in patients with ovarian cancer treated with ACR-368. The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its internally-discovered preclinical stage pipeline programs, consisting of its development candidate, ACR-2316, a selective, dual WEE1/PKMYT1 inhibitor, and additional programs targeting these two critical nodes in the DNA Damage Response, or DDR, pathways.

Our global team operates out of two leading life science clusters, Watertown, MA and Medicon Village in Lund, Sweden.

The Scientist, Signal Transduction and Cancer Biology will be a key member of Acrivon Therapeutics’ Biology Team. This position will be based in Lund, Sweden.

Responsibilities

• Perform research to help elucidate drug mechanism-of-action and resistance mechanisms through experimental design, execution, and data interpretation.
• Perform research to design, screen and analyze data to evaluate drug candidates in our early discovery pipeline.
• Develop novel mechanism-of-action cell-based models that closely mimic human cancer to enable biomarker discovery, answer mechanistic questions and validate biomarkers for therapeutic targets.
• Participate in analysis and evaluation of large phospho-proteomic data sets from drug profiling studies of both cell lines and tissue samples through signal transduction pathway-based analyses.
• Contribute as a member of a diverse and motivated team of researchers across Oncology disciplines and key internal and external collaborators.
• Read and critically evaluate literature to keep abreast of scientific and technological advances.
• Lead or contribute to scientific publications.

Qualifications

• PhD in cell biology, cancer biology or other related scientific discipline with at least 1-2 years of relevant experience in academia or industry.
• Demonstrated expertise in cancer biology, signal transduction, oncogenic signaling pathways, and/or translational biomarker research required.
• Excellent written and interpersonal communication skills with the ability to interact effectively with internal and external colleagues are required.
• Ability to troubleshoot effectively and constructively implement solutions within the broader teams.
• Proven track record of quality research and deep scientific knowledge as evidenced by high impact, peer reviewed publications highly preferred.

Knowledge and hands-on experience in several of the following areas are highly desirable:

• Molecular and Cellular Biology: Western blotting, ELISA, immunofluorescence
• Expertise related to DNA damage response (DDR) signaling, cell cycle regulation and/or DNA replication biology.
• Cell-based assays: tissue culture, cell proliferation and viability assays, reporter assays, flow cytometry and cell cycle analysis, transfection, assays examining DNA damageand DNA replication stress response pathways.
• Demonstrated expertise in development/optimization of in vitro/ex vivo 
• Experience in microscopy.
• Proficiency in data collection/analysis/documentation of all study results in the form of electronic lab notebook reports.

Acrivon Therapeutics is proud to be an equal opportunity employer and to provide equal opportunities to all employees and applicants for employment without regard to race, color, religion, sex or gender identity, national origin, age, disability, sexual orientation, or genetics. In addition to federal law requirements, Acrivon Therapeutics complies with applicable state and local laws governing nondiscrimination in employment.